Pilulka Lékárny has completed an SPO on the START Market of the Prague Stock Exchange
Pilulka Lékárny, a.s. has completed an SPO on the START Market of the Prague Stock Exchange consisting of a capital increase through subscription of new shares. The funds will be used to further develop the company, particularly to strengthen its working capital, to bolster its activities in international markets and to further develop its own e-health solutions.
Since its foundation in 2013, Pilulka has emerged as a leading online pharmacy in central Europe and the operator of a network of franchise and select brick-and-mortar pharmacies in the Czech Republic. Pilulka operates in the Czech Republic, Slovakia and Romania, and entered the Austrian and Hungarian markets in 2022. Pilulka is the number one pharmacy e-shop in-home delivery in the Czech Republic and Slovakia, and among the top three retail pharmacy chains in the Czech Republic.
Oaklins’ team in the Czech Republic acted as an SPO manager in this transaction. The team succeeded in attracting orders from retail investors and high-net-worth individuals.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Learn more